Long-Long Gao

2.3k total citations
25 papers, 228 citations indexed

About

Long-Long Gao is a scholar working on Genetics, Surgery and Epidemiology. According to data from OpenAlex, Long-Long Gao has authored 25 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Genetics, 14 papers in Surgery and 12 papers in Epidemiology. Recurrent topics in Long-Long Gao's work include Inflammatory Bowel Disease (23 papers), Eosinophilic Esophagitis (11 papers) and Microscopic Colitis (7 papers). Long-Long Gao is often cited by papers focused on Inflammatory Bowel Disease (23 papers), Eosinophilic Esophagitis (11 papers) and Microscopic Colitis (7 papers). Long-Long Gao collaborates with scholars based in United States, Canada and Belgium. Long-Long Gao's co-authors include Christopher Gasink, Bruce E. Sands, William J. Sandborn, Jewel Johanns, Jean‐Frédéric Colombel, Willem J. de Villiers, Stephen B. Hanauer, Brian G. Feagan, Subrata Ghosh and Paul Rutgeerts and has published in prestigious journals such as Gastroenterology, The American Journal of Gastroenterology and British Journal of Dermatology.

In The Last Decade

Long-Long Gao

22 papers receiving 224 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Long-Long Gao United States	8	207	120	95	91	18	25	228
Michael Sprakes United Kingdom	6	165 0.8×	131 1.1×	67 0.7×	67 0.7×	16 0.9×	7	216
C Gasink United States	7	175 0.8×	116 1.0×	75 0.8×	118 1.3×	20 1.1×	16	246
Vince Biemans Netherlands	8	315 1.5×	231 1.9×	112 1.2×	104 1.1×	14 0.8×	14	336
An Outtier Belgium	6	149 0.7×	102 0.8×	54 0.6×	60 0.7×	6 0.3×	22	178
Edouard Louis Belgium	6	205 1.0×	152 1.3×	68 0.7×	88 1.0×	21 1.2×	21	268
Sandra El‐Hachem United States	8	204 1.0×	177 1.5×	90 0.9×	34 0.4×	15 0.8×	19	270
Mónica Sierra Spain	4	127 0.6×	83 0.7×	68 0.7×	55 0.6×	7 0.4×	7	157
Joanne Price United States	5	177 0.9×	174 1.4×	49 0.5×	44 0.5×	25 1.4×	6	258
Vikram Kanagala United States	3	187 0.9×	123 1.0×	89 0.9×	73 0.8×	7 0.4×	5	222
Beata Gawdis-Wojnarska Germany	4	133 0.6×	94 0.8×	19 0.2×	108 1.2×	13 0.7×	5	183

Countries citing papers authored by Long-Long Gao

Since Specialization

Citations

This map shows the geographic impact of Long-Long Gao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Long-Long Gao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Long-Long Gao more than expected).

Fields of papers citing papers by Long-Long Gao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Long-Long Gao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Long-Long Gao. The network helps show where Long-Long Gao may publish in the future.

Co-authorship network of co-authors of Long-Long Gao

This figure shows the co-authorship network connecting the top 25 collaborators of Long-Long Gao. A scholar is included among the top collaborators of Long-Long Gao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Long-Long Gao. Long-Long Gao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Linda Stein, Alice B. Gottlieb, April W. Armstrong, et al.. (2025). SPECTREM phase IIIb clinical trial results through week 16: guselkumab efficacy and safety for the treatment of low body surface area, moderate psoriasis with high-impact site involvement. British Journal of Dermatology. 194(1). 25–36.

Alexis, Andrew, Amy McMichael, Neelam A. Vashi, et al.. (2024). Improving Diversity in a Novel Psoriasis Study. JAMA Dermatology. 161(3). 256–256. 5 indexed citations

Afif, Waqqas, Dorota Dajnowiec, Reena Khanna, et al.. (2021). Ustekinumab Therapeutic Drug Monitoring—Impact on Clinical Practice: A Multicenter Cross-Sectional Observational Trial. Digestive Diseases and Sciences. 67(7). 3148–3157. 11 indexed citations

Hanauer, Stephen B., Bruce E. Sands, Brian G. Feagan, et al.. (2019). Tu1723 – Identification of Risk Factors Associated with Loss of Response to Ustekinumab in Crohn's Disease. Gastroenterology. 156(6). S–1099. 2 indexed citations

Sands, Bruce E., Alessandra Oortwijn, James Izanec, et al.. (2019). Tu1725 – Characterization of Patients with Delayed Response to Ustekinumab for Crohn's Disease. Gastroenterology. 156(6). S–1100.

Sands, Bruce E., et al.. (2018). Ustekinumab Improves Productivity and Reduces Work Limitation of Patients With Moderate to Severe Crohnʼs Disease: Results From Three Phase 3 Clinical Trials. The American Journal of Gastroenterology. 113(Supplement). S352–S352. 1 indexed citations

Gasink, Christopher, et al.. (2018). Exposure-Response to SC Ustekinumab in Moderate –Severe Crohnʼs Disease: Results From the IM-UNITI Maintenance Study. The American Journal of Gastroenterology. 113. S2–S2. 3 indexed citations

Sands, Bruce E., Brian C. Kramer, Christopher Gasink, et al.. (2018). Long-Term Efficacy of Ustekinumab With and Without Concomitant Immunosuppressants for Crohnʼs Disease: Results From IM-UNITI Long-Term Extension Through 2 Years. The American Journal of Gastroenterology. 113(Supplement). S330–S330. 1 indexed citations

Hanauer, Stephen B., Christopher Gasink, Timothy Hoops, et al.. (2018). Sa1734 - Impact of Prior Surgical History on Efficacy with Ustekinumab in Crohn's Disease: A Subgroup Analysis of the Phase 3 Uniti Studies. Gastroenterology. 154(6). S–373. 1 indexed citations

10.

Sandborn, William J., Bruce E. Sands, Christopher Gasink, et al.. (2018). Sa1743 - Reduced Rates of Crohn's- Related Surgeries, Hospitalizations and Alternate Biologic Initiation with Ustekinumab in the Im-Uniti Study Through 2 Years. Gastroenterology. 154(6). S–377. 5 indexed citations

11.

Sandborn, William J., Paul Rutgeerts, Christopher Gasink, et al.. (2017). Long-Term Efficacy and Safety of Ustekinumab for Crohn’s Disease: Results From Im-Uniti Long-Term Extension Through two Years. Gastroenterology. 152(5). S585–S585. 4 indexed citations

12.

Sands, Bruce E., Christopher Gasink, Long-Long Gao, et al.. (2017). Fistula Healing in Pivotal Studies of Ustekinumab in Crohn's Disease. Gastroenterology. 152(5). S185–S185. 60 indexed citations

13.

Feagan, Brian G., Christopher Gasink, Paul Pollack, et al.. (2017). Effect of Maintenance Ustekinumab on Corticosteroid-Free Clinical Outcomes in Patients with Crohn’s Disease. Gastroenterology. 152(5). S595–S595. 2 indexed citations

14.

Sandborn, William J., Christopher Gasink, Marion Blank, et al.. (2016). O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohnʼs Disease Refractory to Anti-TFNα. Inflammatory Bowel Diseases. 22. S1–S1. 38 indexed citations

15.

Sandborn, William J., Brian G. Feagan, Christopher Gasink, et al.. (2016). 768 A Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Ustekinumab Maintenance Therapy in Moderate - Severe Crohn's Disease Patients: Results From IM-UNITI. Gastroenterology. 150(4). S157–S158. 13 indexed citations

16.

Sands, Bruce E., Chenglong Han, Christopher Gasink, et al.. (2016). Tu2006 Ustekinumab Improves General Health Status and Disease-Specific Health Related Quality of Life of Patients with Moderate to Severe Crohn's Disease: Results from the UNITI and IMUNITI Phase 3 Clinical Trials. Gastroenterology. 150(4). S1004–S1004. 10 indexed citations

17.

Sandborn, William J., Christopher Gasink, Long-Long Gao, et al.. (2016). Tu1934 Assessment of Serum C-Reactive Protein, Fecal Lactoferrin, and Fecal Calprotectin in Patients With Moderate-Severely Active Crohns Disease: Results From the IM UNITI Maintenance Study. Gastroenterology. 150(4). S982–S982. 1 indexed citations

18.

Gasink, Christopher, Daphne Chan, Long-Long Gao, Brad Schenkel, & Chenglong Han. (2013). Sa1211 Assessment of Sleep Impairment in Patients With Crohn's Disease: Results From the Ustekinumab Certifi Study. Gastroenterology. 144(5). S–231. 7 indexed citations

19.

Toedter, Gary, Xiaoying Wu, Long-Long Gao, & Christopher Gasink. (2011). Reductions in Fecal Calprotectin and Lactoferrin Following Ustekinumab Induction Therapy in Patients With Moderate to Severe Crohn's Disease Who Have Previously Failed or Been Intolerant of TNF Antagonist Therapies. Gastroenterology. 140(5). S–264. 4 indexed citations

20.

Sandborn, William J., Christopher Gasink, Long-Long Gao, et al.. (2011). A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase2b Study of Ustekinumab, a Human Monoclonal Antibody to IL-12/23p40, in Patients With Moderately to Severely Active Crohn's Disease: Results Through Week 22 From the Certifi Trial. Gastroenterology. 140(5). S–109. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact